OnDosis Årsstämma 24 april 2024
OnDosis Årsstämma 24 april 2024: Förslag till beslut om införande av Personaloptionsprogram, riktad emission av teckningsoptioner och godkännande av överlåtelse av teckningsoptioner
OnDosis Årsstämma 24 april 2024: Förslag till beslut om införande av Personaloptionsprogram, riktad emission av teckningsoptioner och godkännande av överlåtelse av teckningsoptioner
See attached documents
Vi summerar ett dynamiskt 2023 i en position av styrka och ser fram emot ett 2024 där vårt fokus går från produktutveckling och skalning av tillverkning under våren, till fokus på produktion i kommersiell skala, kliniska studier och förberedelser för regulatoriska ansökningar under hösten.
Aktieägarna i OnDosis AB (publ), org.nr 559113-1825, kallas härmed till årsstämma onsdagen den 24 april 2024 kl. 10.00 i Bolagets lokaler i GoCo House, 5 tr, Gemenskapens gata 9 i Mölndal.
Insläpp och registrering sker vid entrén kl. 09.30.
Press release
Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment
CAMBRIDGE, UK; GOTHENBURG, Sweden – 29 November 2023 – Camallergy, a pioneer in developing oral immunotherapy treatments for food allergies, and OnDosis, a leader in intelligent dosing of oral solid medicines, are excited to announce a strategic collaboration.
This
Årsredovisning OnDosis samt villkor bilaga A / Annual report OnDosis and terms appendix A
Årsredovisning 2022 / Annual report 2022 OnDosis AB
VILLKOR FÖR TECKNINGSOPTIONER SERIE 2023:A I ONDOSIS AB TERMS AND CONDITIONS FOR WARRANTS SERIES 2023:A IN ONDOSIS AB
OnDosis, a MedTech company aiming to revolutionize the way patients take their medicines, announced the issuance by the USPTO of its 1st patent relating to the company’s device technology, a first in category Dosage Manager.
Emplicure AB och OnDosis AB utvärderar gemensamma utvecklingsmål för oral dosering av aktiva substanser baserade på bolagens respektive unika teknologier inom formulering och dosering.
TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and
OnDosis, ett svenskt medicinteknikbolag som utvecklar en unik device-plattform för flexibel och individanpassad dosering av läkemedel, och Stardots, ett svenskt digitalt hälsobolag som utvecklar produkter inom neurologi, meddelar idag att bolagen ingått ett strategiskt samarbete. Avsikten är att kombinera bolagens banbrytande teknologier för att möjliggöra utveckling av unika produkter för beh
OnDosis, a Swedish Life science company developing a new drug/device technology platform, announced today that the Company has completed a private placement of SEK 75 million. Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen
Aktieägarna i OnDosis AB, org.nr 559113-1825 (”OnDosis” eller ”Bolaget”), kallas härmed till årsstämma tisdagen den 28 juni 2022 kl. 10.00 i Bolagets lokaler på AstraZeneca Bio VentureHub, Pepparedsleden 1 i Mölndal. Insläpp och registrering sker vid AstraZeneca KC entrén kl. 09:45.
The shareholders of OnDosis AB, reg. no. 556582-6558, (“OnDosis” or the “Company”) are hereby given notice of Ann
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
The private placement follows the successful expansion of the strategic collaboration between OnDosis and Tiefenbacher
Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.
Tiefenbacher Group is a pioneering healthcar
Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
OnDosis wants to revolutionize the way we take our medicines. The idea is that every single patient, in the easiest possible way, shall get precisely the right amount of medicine and thus lead a better life. Now the company begins a cooperation with Opatus, whose digital tool objectively scales symptoms of ADHD patients. In addition, OnDosis recently received a double recognition at the large
Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment
Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.
Pepparedsleden 1
431 50 Mölndal
Sweden